Above all Cialis, which fights erectile dysfunction and Crestor, which serves to reduce cholesterol
On November 12, thirteen patents for drugs that are nothing short of important will expire. Above all that of Cialis, which treats erectile dysfunction, in class C, i.e. with a prescription but paid for by the patients, but in the list also antihypertensive and anticholesterol drugs, drugs against osteoarthritis and benign prostatic hypertrophy. Their price should collapse, thanks to the use of generics.
No other molecule in that category collects so much from Italians, about 146 million a year, recalls Repubblica speaking of Cialis, Viagra's "pharmaceutical opponent".
The turnover of these 13 patents is over one billion euros, almost entirely borne by the national health service given that they are reimbursed medicines, in category A. The estimate is that the entry of the generic knock down the prices of around the 60%. Calculating what the savings will be is quite easy: 600 million euros.
Do not underestimate the impact of Crestor, i.e. rosuvastatin, which can be sold by any pharmaceutical company from next December 30th. It is used to reduce cholesterol and is widely used. Every year the system spends around 270 million euros to buy it.
Related news: Patents expire, for companies -65 billion dollars by 2019
Generic drugs market, here are the growing realities around the world
The main patent expiries
2017
- Rosuvastatin (Crestor)
- RUPATADINE (Pafinur)
- OLMESARTAN(Olmetec)
- Dutasteride (Avodart/Duagen)
- TADALAFIL (Cialis)
- BIMATOPROST
- CASPOFUNGIN
- BOSENTAN
- ERTAPENEM
- TRAMADOL + PARACETAMOL
- ETORICOXIB
- TIGECYCLINE
- PEGFILGRASTIM (Neulasta)*
- ABATACEPT (Orencia)
- OLOPATADINE
- VALGANciclovir
2018
- Everolimus (Certican)
- Adalinumab (Humira)
- Ezetimibe (Ezetrol)
- SILODOSOSIN
- EFAVIRENZ/EMTRICITABINE/TENOFOVIR
- OPEN REPIPANT
- SOLIPHENACIN
2019
- ATAZANAVIR (Reyataz)
- BORTEZOMIB (Velcade)
- ABACAVIR/LAMIVUDINE (Kivexa)
- POSACONAZOLE
- GEFITINIB
- CHINACALCET HYDROCHLORIDE
- THALIDOMIDE
- FOSAMPRENAVIR CALCIUM SALT
- VINFLUNINA
Source 1: List of complementary protection certificates (CCP) granted and expiring starting from 01/01/2015
Source 2: QuintilesIMS, MAT 11/2016
* The sources in our possession are not unique on the expiration date of this product.
This list does not provide certification of patent expiration, but merely collects dates from available sources
Ministry of Economic Development - Italian Patent and Trademark Office - DM 14/01/2013
- legislative decree 10 February 2005, n. 30 bearing the industrial property code
- art. 15 of the law of 12 December 2001, n. 273 art. 61
- art. 9 paragraph 2-bis of the decree law 31 December 2007, n. 248 converted, with amendments, by law February 28, 2008, n. 31
- art. 11 of the decree-law of 13 September 2012, n. 158 converted, with amendments, by law 8 November 2012, n. 189
CCP list 2015 – Downloads»
Decree 23 December 2015 – Downloads»
